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Abstract
Background: Lipodystrophic syndromes are uncommon medical conditions which are normally associated with
metabolic disorders, such as diabetes mellitus, dyslipidemia, and fatty liver disease. These complications are
generally difficult to treat, particularly diabetes, due to severe insulin resistance. We present two case reports of
successful treatment of diabetes with glucagon-like peptide-1 analogues in patients with clinical features of
lipodystrophic syndromes.
Case presentation: Two white women aged 49 and 60 years manifested marked central body fat deposition
with severe lipoatrophy of their limbs and buttocks and pronounced acanthosis nigricans. They had hypertension,
dyslipidemia, fatty liver disease, and poorly controlled diabetes (glycated hemoglobin 8.3% and 10.2%, respectively)
despite the use of three classes of oral antidiabetic drugs taken in combination in the first case, and high doses of
insulin in the second case. Four months after the addition of glucagon-like peptide-1 analogue to their previous
treatment they both showed a pronounced improvement in metabolic control (glycated hemoglobin 5.6% and
6.2%, respectively). In the first case, a weight loss of nearly 30 kg was recorded.
Conclusions: We intend to demonstrate that glucagon-like peptide-1 analogues could be a valuable tool for
patients with lipodystrophic disorders, probably by improving body fat distribution, with favorable results in
insulin-sensitivity and glycemic control.
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Background
Lipodystrophic syndromes are rare disorders charac-
terized by selective loss of adipose tissue, mainly from
subcutaneous compartments. Lipoatrophy may vary
from being partial, co-existing with adipose tissue depots
in ectopic sites, to generalized [1]. These syndromes are
usually linked with severe metabolic complications, such
as insulin resistance, diabetes mellitus, dyslipidemia,
hepatic steatosis, and hypertension [2, 3]. Loss of adi-
pose tissue seems to give rise to both lipodystrophy
and metabolic disorders [2], which suggests that it is
the absence of fat tissue and the consequent leptin
deficiency that leads to insulin resistance [4, 5].
Furthermore, adipocytes provide a benign location to
accumulate lipids and, thus, when they are absent,
lipids will store in the liver, muscle, and ectopic tis-
sues, causing significant metabolic complications [6].
Patients may present acanthosis nigricans, acromega-
loid features, muscular hypertrophy, and hirsutism in
the context of ovarian hyperandrogenism: polycystic
ovary syndrome (PCOS) [2, 7]. Over the last decades,
several causative genetic mutations have been identi-
fied in patients with lipodystrophies. Nevertheless,
lipodystrophy is a clinical diagnosis which is based on
a physical examination, and many such patients
present no mutations of identified genes, suggesting
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that other genes are involved and have not yet been
deciphered [8]. The treatment of complications involves
classical intervention strategies, however, owing to the
severity of insulin resistance, managing such complica-
tions can be challenging. Glucagon-like peptide-1
(GLP-1) analogues stimulate glucose-dependent insulin
secretion and suppress inappropriately elevated gluca-
gon secretion, thus improving glucose homeostasis.
These analogues also delay gastric emptying and act
centrally to promote satiety, thus reducing food intake,
which leads to weight loss. This loss seems to result
from a reduction in fat mass, rather than lean tissue
mass [9], with a preferential decrease in visceral fat
[10]. We describe two clinical cases of diabetes in pa-
tients with lipodystrophic features who were success-
fully treated with GLP-1 analogues.
Case presentation
Case 1
A 49-year-old white woman was referred to our Endo-
crinology department for obesity. She presented dia-
betes treated with metformin 2500 mg/day, sitagliptin
100 mg/day, and gliclazide 120 mg/day. She had
hypertension, dyslipidemia, hyperuricemia, fatty liver
disease, and obstructive sleep apnea. Furthermore, she
was being treated for a major depression, partly moti-
vated by body image problems. She weighed 89.5 kg,
had a body mass index (BMI) of 33.7 kg/m2, and
presented an evident abdominal fat deposition (waist
circumference 123 cm), with markedly reduced adi-
pose tissue in her limbs and buttocks. She had a round
face with cervical acanthosis nigricans, and an accu-
mulation of fat in the chin and in the cervicodorsal
and supraclavicular regions. Laboratory tests revealed
glycated hemoglobin (A1c) 8.3%; total cholesterol
273 mg/dL (<200), high-density lipoprotein (HDL)
cholesterol 49 mg/dL (>60), low-density lipoprotein
(LDL) cholesterol 196 mg/dL (<130), triglycerides
350 mg/dL (<150), under statin; and uric acid 6.9 mg/
dL (2.3 to 6.1). She presented normal 24-hour urinary
free cortisol of 39 mcg/24 hours (36 to 137) and an
overnight dexamethasone suppression test recorded a
serum cortisol of 0.4 mcg/dL (<1.8mcg/dL). She
started taking exenatide 2 mg once a week, with good
tolerance. Sitagliptin was suspended, while maintain-
ing the other antidiabetic drugs. After 4 months of
therapy, she lost 29.2 kg (approximately 33% of her
initial body weight) and her A1c was 5.6%. The results
of genetic tests for mutations in LMNA gene and
PPAR-gamma gene were negative.
Case 2
A 60-year-old white woman was observed in our Endocrin-
ology department for diabetes. She presented hypertension,
dyslipidemia, fatty liver disease, severe obstructive sleep
apnea, depressive disorder, and a history of a previous
ischemic stroke. She had poor glycemic control, with
A1c values between 9 and 11% over recent years, re-
quiring several medication adjustments. She was
treated with metformin 2000 mg/day, and a total daily
dose of insulin of nearly 240 units in a basal-bolus regi-
men. Her regimen was: neutral protamine Hagedorn
(NPH) insulin three times daily (60 units in the morn-
ing, 50 units at lunch, and 46 units at night); insulin
aspart at mealtimes (21 units at breakfast, 24 units at
lunch, 11 units at afternoon snack, and 27 units at din-
ner); and a correctional insulin dose was added, based
on her pre-prandial glucose value, resembling a sliding
scale. Her insulin sensitivity factor was 10. Her physical
examination revealed that she was overweight (weight
75.9 kg, BMI 33.7 kg/m2), with central body fat depos-
ition (waist circumference 105 cm) and prominent
lipoatrophy of her limbs and buttocks. She presented
pronounced cervical and axillary acanthosis nigricans,
and hirsutism. Laboratory tests showed an A1c of
10.2% and dyslipidemia: total cholesterol 226 mg/dL
(<200), HDL cholesterol 51 mg/dL (>60), LDL choles-
terol 131 mg/dL (<130), triglycerides 221 mg/dL
(<150), despite being medicated with statin. She had
mildly elevated liver enzymes levels: aspartate amino-
transferase 67 U/L (10 to 31), alanine aminotransferase
76 U/L (10 to 31), gamma glutamyl transferase 321 U/L
(7 to 32), and alkaline phosphatase 175 U/L (30 to 120).
Her renal function was normal. Cushing syndrome had
been excluded: 24-hour urinary free cortisol 80.1 mcg/
24 hours (36 to 137). An overnight dexamethasone sup-
pression test registered serum cortisol of 0.8 mcg/dL
(<1.8 mcg/dL). Treatment with liraglutide was initiated,
in addition to insulin therapy, at 0.6 mg every day for a
week, titrated to 1.2 mg for the next week, and then to
1.8 mg daily. An insulin dose reduction of 20 units was
recommended at the time that treatment with liraglu-
tide was initiated. She reported no side effects, such as
nausea, vomiting, diarrhea, or hypoglycemia. After
3 months of therapy, a total daily insulin dose of 200
units, metformin 2000 mg/day, and liraglutide 1.8 mg
daily resulted in a much improved glycemic control (A1c
6.2%). She lost 1.8 kg. Similarly, the results of genetic tests
for mutations in LMNA gene and PPAR-gamma gene
were negative.
Conclusions
A remarkable feature of lipodystrophic syndromes is the
clinical heterogeneity regarding the extent and location
of adipose tissue loss. Nevertheless, with very few excep-
tions, the majority of lipodystrophy disorders are associ-
ated with impaired insulin sensitivity and diabetes [8],
which are complications that are difficult to treat with
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classical therapeutic options. In the two cases described,
diabetes was successfully treated with the addition of a
GLP-1 analogue to the previous therapeutic regimen.
GLP-1 receptors (GLP-1R) are expressed in the arcuate
and paraventricular nucleus of the hypothalamus, and
recent evidence indicated that activation of arcuate
GLP-1R sensitizes the liver to insulin and reinforces in-
sulin action to suppress endogenous glucose production
[11]. Furthermore, GLP-1 analogues seem to amplify
insulin signaling in adipocytes by upregulating insulin
signaling molecules. Liraglutide has been shown to
ameliorate insulin resistance through upregulation of
glucose transporter-4 and to decrease oxidative stress
and inflammation. It has also been shown to improve
endothelial and cardiac function, which might result in
increasing systemic insulin sensitivity [12]. Data from
studies in diabetic rats showed that exenatide inhibits
hepatic gluconeogenesis and increases glucose uptake
in the peripheral skeletal muscle with improvement of
hepatic and extrahepatic insulin resistance [13]. Ac-
cording to some studies, these drugs significantly influ-
ence fat distribution, and even a short course of
treatment results in a significant decrease of subcutane-
ous and visceral fat deposits [10, 14]. The effect starts
showing shortly after the beginning of treatment [9, 15].
The extent of weight reduction is not always as significant
as that of the result described in the first case, but it has
been shown that important health benefits can be
achieved with modest weight loss [10]. For patients taking
insulin, the addition of GLP-1 analogue may help offset
weight gain, or even promote some weight loss and reduce
insulin needs, with an improvement in glycemic control
[16]. In fact, in our second case, there was a small reduc-
tion in weight, although the patient achieved target levels
of A1c with lower insulin requirements. The potential
predictors of different weight loss response with GLP-1
analogues treatment remain unidentified. A study
evaluating the impact of genetic variability of GLP-1R
on weight response to liraglutide demonstrated that
some polymorphisms are associated with individual dif-
ferences regarding weight loss response in obese
women with PCOS. Thus, as GLP-1R is a major target
for the GLP-1 analogues, its genetic variability could be
hypothetically linked with the different response to the
weight-reducing potential of these drugs in a clinically
homogenous population [17].
As far as we know, our cases are the first reports of the
treatment of patients with lipodystrophic syndromes not
human immunodeficiency vírus (HIV)-associated, with se-
vere insulin resistance, with GLP-1 analogues. We intend
to demonstrate that GLP-1 analogues could be used as
new tools for the treatment of these metabolic and adipose
tissue disorders, reducing fat mass and insulin resistance,
decreasing insulin requirements, and improving A1c.
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